Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 6912345...102030...Last »

Judge dismisses two Express Scripts claims

A federal judge dismissed two of the six counterclaims that Express Scripts raised in health insurer’s Anthem’s $15 billion lawsuit claiming it charged too much for drugs.

Read More »

Merck must face renewed Fosamax warning claims

A federal appeals court revived claims by plaintiffs accusing Merck & Co. of failing to adequately warn about risks of thigh bone fractures associated with Fosamax.

Read More »

Allergan signs deal with Editas for gene-editing-based eye treatments

Allergan plc said it would get exclusive access and the option to license up to five of Editas Medicine Inc.’s experimental gene-editing-based eye treatments under a research and development deal between the two companies.

Read More »

Ackman Is Finally Done With Valeant, Takes $2.8 Billion Loss and Will Step Down From Board

And with a $2.8 billion loss, investor Bill Ackman is done with Valeant Pharmaceuticals. A once staunch defender of the beleaguered company, Ackman said he has sold all of his shares of Valeant stock and will not stand for re-election to the company board of directors.

Read More »

Mylan gains clear pathway for Herceptin biosimilar

Mylan reached a settlement providing “a clear pathway” for the launch of its biosimilar version of Roche’s top-selling breast cancer drug Herceptin in major markets.

Read More »

Argos Cuts Staff by 38 Percent

Durham, N.C.-based Argos Therapeutics filed with the U.S. Securities and Exchange Commission that it plans to cut its workforce by 38 percent.

Read More »

Judge Halts Immunomedics-Seattle Genetics Deal

Shares of Immunomedics jumped more than 12 percent after a judge temporarily halted its licensing deal with Seattle Genetics.

Read More »

Bristol-Myers Squibb Appoints New R&D Chief

Bristol-Myers Squibb tapped a new chief scientific officer – Thomas J. Lynch – to succeed Francis Cuss, who is retiring.

Read More »

Apotex Announces $184 Million Investment to Grow U.S. Manufacturing Presence; Expansion Plan Comprises Company’s Largest Investment in the United States

Advanced R&D, Manufacturing, and Packaging Facility to Serve as U.S. Headquarters; Initially Expected to Create Minimum of 150 Full-Time Jobs BROWARD COUNTY, Fla., March 8, 2017 /PRNewswire/ — Today Apotex Inc., the largest Canadian owned pharmaceutical company, announced the details of a $184 million U.S. expansion plan, including the development of a new R&D center […]

Read More »

Former Millennium and FORUM Pharma CEO Resurfaces to Helm Massachusetts Biotech XTuit

March 8, 2017 By Mark Terry, Breaking News Staff Waltham, Mass.-based XTuit Pharmaceuticals announced today that Deborah Dunsire was stepping in as president, chief executive officer, and board member. She is replacing replacing interim chief executive officer Alan Crane, a partner with Polaris Partners. Dunsire is well known within the biotech industry. She spent […]

Read More »

Pfizer Eyes $100 Million Expansion, New Jobs in North Carolina

Pfizer has its eyes set on a possible $100 million investment to expand a plant in Sanford, N.C. with a focus on gene therapy, according to the Triangle Business Journal. The investment would include the addition of 50 new jobs.

Read More »

House panels to launch fight in Congress over Obamacare replacement

A potentially lengthy U.S. legislative fight over replacement of the Obamacare health law got underway as two House of Representatives committees begin negotiating over changes to a Republican plan backed by President Donald Trump.

Read More »

J&J wins trial in talc product liability lawsuits

A state court jury in Missouri returned a verdict in J&J’s favor in the latest trial arising out of lawsuits alleging its talc-based products can increase ovarian cancer risk.

Read More »

Sanofi Pasteur Inks $645 Million RSV Deal With AstraZeneca’s MedImmune

Paris-based Sanofi Pasteur announced that it had inked a development agreement with MedImmune, the research-and-development art of AstraZeneca.

Read More »

Novartis cancer unit races to catch up with rivals

Novartis is making progress in its bid to catch rivals developing drugs that harness the immune system to fight cancer, one of its top research scientists told Reuters.

Read More »

FDA warns Pfizer over contaminated drugs at Kansas plant

The U.S. FDA said Pfizer’s process for manufacturing sterile injectable drugs at a plant in McPherson, Kansas was “out of control” and put patients at risk, according to a warning letter.

Read More »

Troubled Cempra Slashes 67 Percent of Workforce

Antibiotic drugmaker Cempra Inc. will terminate 67 percent of its employees following the U.S. FDA’s rejection of solithromycin, an oral and intravenous drug being evaluated for the treatment of community-acquired bacterial pneumonia (CABP) in adults.

Read More »

Pfizer subpoenaed in U.S. over patient assistance plans

Pfizer Inc. said it received subpoenas from the U.S. Attorney’s Office for the District of Massachusetts related to its support for organizations that provide financial help to Medicare patients.

Read More »

The End of the Road: NovaDel Pharma to Dissolve

After taking more than a year to sell off its insomnia medication ZolipiMist to Amherst Pharmaceuticals, NovaDel Pharma has dissolved the company.

Read More »

Thermo Fisher did not infringe genetic-test patent

The U.S. Supreme Court cleared a subsidiary of biotech company Thermo Fisher Scientific Inc. of infringing a genetic-testing kit patent held by Promega Corp.

Read More »

Page 1 of 6912345...102030...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2017 Focus: Top 10 Pipelines, Agenda 2017 and more!


Ad Right Bottom

Password Reset
Please enter your e-mail address. You will receive a new password via e-mail.

Main Navigation